Related references
Note: Only part of the references are listed.Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone
Issa J. Dahabreh et al.
CLINICAL TRIALS (2008)
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose - Results of the Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
G. R. Dagenais et al.
DIABETES CARE (2008)
Pioglitazone and heart failure: Results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction
Thomas D. Giles et al.
JOURNAL OF CARDIAC FAILURE (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes
Christos Sambanis et al.
ACTA DIABETOLOGICA (2008)
Peroxisome proliferator-activated receptor-γ is involved in the control of renin gene expression
Vladimir T. Todorov et al.
HYPERTENSION (2007)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus
Y. Tuerkmen Kemal et al.
ACTA DIABETOLOGICA (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Diabetic cardiomyopathy revisited
Sihem Boudina et al.
CIRCULATION (2007)
Cardiovascular safety of rosiglitazone
Ronald L. Krall
LANCET (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure
Henry J. Dargie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
Prevalence of diabetes and impaired fasting glucose in adults in the US population - National Health and Nutrition Examination Survey 1999-2002
Catherine C. Cowie et al.
DIABETES CARE (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): Study design and protocol
PD Home et al.
DIABETOLOGIA (2005)
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
YF Guan et al.
NATURE MEDICINE (2005)
Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention
H Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men
A Zanchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure
RW Nesto et al.
DIABETES CARE (2004)
Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone
S Ogawa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes
MS Sutton et al.
DIABETES CARE (2002)
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats -: Role of peroxisome proliferator-activated receptor-γ
QN Diep et al.
CIRCULATION (2002)
Epidemiology, aetiology, and prognosis of heart failure
JJ McMurray et al.
HEART (2000)
Share Paper
